title: [Bacteremia with granulocytopenia--microbiology and empiric antibiotic treatment].
abstract: This article sums up a retrospective analysis of 84 episodes of bacteraemia in acute leukaemia patients with severe neutropenia in a Norwegian teaching hospital during the period 1990-95. Gram negative bacteria represented 54% of the blood culture isolates, all of which were susceptible to aminoglycosides, and nearly all to ceftazidime and imipenem. Penicillin/aminoglycoside was used as initial therapy in 43% of the episodes. Initial empiric therapy was modified in 52% of the events. Only 15% of patients receiving the penicillin/aminoglycoside combination actually had infections with organisms susceptible to penicillin. Only 2% of patients with gram negative infections received initial synergistic treatment with two effective drugs. Mortality from infections was 8% in acute leukaemia patients with documented bacteraemia. Deaths mainly occurred in patients with terminal leukaemia disease. Late breakthrough bacteraemias with Stenotrophomonas maltophilia and Pseudomonas aeruginosa caused 50% of all fatal infections. The analysis suggests that no patients died during initial bacteraemia with penicillin-resistant organisms treated with penicillin/aminoglycoside. The antibiotic susceptibility of the isolated bacteria was favourable compared to what has been found in other countries. For the time being, we believe that the ecological advantages of using penicillin/aminoglycoside as initial empiric treatment of febrile neutropenia are greater than the disadvantages.
authors.affiliation: Medisinsk avdeling, Regionsykehuset i Trondheim.
authors.forename: J
authors.initials: J
authors.lastname: Hammerstrøm
authors.forename: T
authors.initials: T
authors.lastname: Jacobsen
mesh_terms: D000380:Agranulocytosis / Q000150:complications* / Q000188:drug therapy; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D016470:Bacteremia / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination; D005334:Fever / Q000188:drug therapy; D016905:Gram-Negative Bacterial Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D010403:Penicillin Resistance; D010406:Penicillins / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D010406:Penicillins